BAR HARBOR, Maine — Over the past year, billions of dollars and countless hours of research have gone into developing a vaccine for COVID-19.
Not every virus, illness, or disease gets that kind of attention. Rare diseases receive relatively little attention and investment from pharmaceutical companies.
By United States standards, a “rare and orphan disease” is one that affects fewer than 200,000 people. Read more
The Bar Harbor Planning Board has approved a plan by the Jackson Laboratory to build a 20,000-square-foot expansion to its Rare Disease Translational...
Researchers at Bigelow Laboratory for Ocean Sciences believe algae can make a big splash in the agricultural, aquaculture and pharmaceutical industries,...
The University of Maine System said this week it will work with a national consultant to study the feasibility of launching the state’s...